NanoSpot.ai’s agreement with the Greek company Opto enables the commercialization and distribution in Europe of NanoSpot.ai’s line of antibody tests, including the SARS-CoV-2 test pictured here.
SALT LAKE CITY—NanoSpot.ai, a producer of digital agglutination-based antibody tests, announced that it has entered into a commercial and distribution agreement with Opto, an Athroa company and pioneer provider of connected diagnostics. This partnership is a result of a joint clinical study performed in Athens, Greece, that confirmed the power of the NanoSpot.ai platform and the efficacy of the company’s products.
Opto will become the first commercial partner of Nanospot.ai globally. This agreement covers distribution in Greece of the NanoSpot.ai line of products, including the NanoSpot.ai SARS-CoV-2 Total Antibody Test.
The NanoSpot.ai SARS-CoV-2 Total Antibody Test, which was originally developed through a partnership between the University of Utah, ARUP Laboratories, and Techcyte Inc., uses an agglutination-based method combined with an artificial intelligence (AI)-driven mobile application to deliver semiquantitative antibody results at the point of care. This unique approach helps enable accurate (98.0% sensitivity and 100% specificity) diagnostic results without the need for diagnostic equipment. The test requires an Internet connection and takes less than three minutes to perform, from sample collection to result. The NanoSpot.ai SARS-CoV-2 Total Antibody Test obtained a Conformité Européenne (CE) mark in May 2022.
"This exclusive distribution agreement supports our mission to make antibody insights more accessible globally,” said Rian Wendling, CEO of NanoSpot.ai. “We are excited to provide NanoSpot.ai solutions to our customers and are thrilled to make semiquantitative antibody testing simple and achievable."
Throughout the next year, NanoSpot.ai and Opto will continue their collaboration to introduce the SARS-CoV-2 Total Antibody Test and future solutions and to support adoption in Greece and other parts of Europe.
NanoSpot.ai unlocks the unique advantages of agglutination-based testing to bring low-cost, quantitative, and ultra-fast blood-based diagnostics to any environment. Its AI-enabled platform provides personalized insights anywhere an Internet connection is available.